Scribe Therapeutics Q3 2026: EPS Beat, Revenue Miss Explained

Scribe Therapeutics reported a GAAP net loss of $0.68 per share for the third quarter of 2026, beating the consensus estimate of $1.03 per share. That bottom-line outperformance stands out for a clinical-stage company in its first quarterly report as a public company, following a Nasdaq IPO completed on July 24, 2026.

Revenue tells a different story. Collaboration revenue of $1.64 million missed the $3.72 million consensus, extending a decline that has run through each of the five most recent quarters. The driver is a wind-down in reimbursable R&D activity under the Eli Lilly collaboration.

Costs shifted in opposite directions. R&D expense eased on lower employee-related and external costs, partly offset by CIRM grant funding recorded as a reduction. G&A expense climbed to $4.20 million, reflecting stock-based compensation and the new overhead that comes with being a publicly traded company.

The IPO and a concurrent private placement from Sanofi generated about $155.5 million in aggregate gross proceeds, leaving Scribe with $174.2 million in cash, equivalents, and marketable securities. Management says that runway extends into the first half of 2029, which is designed to carry the company past a key clinical milestone. CEO Benjamin Oakes noted that the Sanofi collaboration was also expanded during the quarter to include ELXR epigenetic silencing technology.

The near-term catalyst investors are focused on is initial Phase 1 data from STX-1150, Scribe's ELXR-based epigenetic silencing of PCSK9 for LDL-C lowering. Single-ascending-dose data on safety, tolerability, and LDL-C reduction are expected in the first half of 2027. Primate data presented at AHA 2026 showed that a single 0.75 mg/kg dose produced more than 50% LDL-C reduction sustained for two years, a result that frames what the human trial is being measured against.